Literature DB >> 24960415

Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy.

Max M Wattenberg1, Ahmed Fahim, Mansoor M Ahmed, James W Hodge.   

Abstract

There is increasing evidence of the potential for radiation therapy to generate antitumor immune responses. The mechanisms of this immune-activating potential include actions on tumor cells such as immunogenic cell death and phenotypic change. Radiation modulates tumor cell surface expression of cell death receptors, tumor-associated antigens and adhesion molecules. This process of immunomodulation sensitizes tumor cells to immune-mediated killing. Radiation also affects immune compartments, including antigen-presenting cells, cytotoxic T lymphocytes and humoral immunity, leading to specific antitumor immune responses. Recognizing the importance of immunity as a potentiator of response to radiation leads to rational augmentation of antitumor immunity by combining radiation and immunotherapy. Targeted immunotherapy manipulates the immune system in a way that best synergizes with radiation. This article discusses the ability of radiation monotherapy to induce antitumor immunity, with a focus on the effect of radiation on antigen-presenting cells and cytotoxic T lymphocytes. We define two important responses generated by tumor cells, immunogenic cell death and immunomodulation, both of which are radiation dose-dependent. In conclusion, we describe the translation of several combination therapies from the preclinical to the clinical setting and identify opportunities for further exploration.

Entities:  

Mesh:

Year:  2014        PMID: 24960415      PMCID: PMC4128341          DOI: 10.1667/RR13374.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  60 in total

1.  Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.

Authors:  Raquibul Hannan; Huagang Zhang; Anu Wallecha; Reshma Singh; Laibin Liu; Patrice Cohen; Alan Alfieri; John Rothman; Chandan Guha
Journal:  Cancer Immunol Immunother       Date:  2012-05-27       Impact factor: 6.968

2.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Authors:  Mitomu Kioi; Hannes Vogel; Geoffrey Schultz; Robert M Hoffman; Griffith R Harsh; J Martin Brown
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

3.  Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.

Authors:  J Wolfers; A Lozier; G Raposo; A Regnault; C Théry; C Masurier; C Flament; S Pouzieux; F Faure; T Tursz; E Angevin; S Amigorena; L Zitvogel
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.

Authors:  Laurence Zitvogel; Oliver Kepp; Laura Senovilla; Laurie Menger; Nathalie Chaput; Guido Kroemer
Journal:  Clin Cancer Res       Date:  2010-04-26       Impact factor: 12.531

5.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

6.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

7.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701

8.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Authors:  Anna R Kwilas; Renee N Donahue; Michael B Bernstein; James W Hodge
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

9.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

10.  The confluence of radiotherapy and immunotherapy.

Authors:  Byron Burnette; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Front Oncol       Date:  2012-10-16       Impact factor: 6.244

View more
  30 in total

1.  Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.

Authors:  Joseph W Kim; Min Sun Shin; Youna Kang; Insoo Kang; Daniel P Petrylak
Journal:  Clin Genitourin Cancer       Date:  2017-10-24       Impact factor: 2.872

Review 2.  Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Authors:  Maureen L Aliru; Jonathan E Schoenhals; Bhanu P Venkatesulu; Clark C Anderson; Hampartsoum B Barsoumian; Ahmed I Younes; Lakshmi S K Mahadevan; Melinda Soeung; Kathryn E Aziz; James W Welsh; Sunil Krishnan
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

3.  Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients.

Authors:  C Yuan; Q Wang
Journal:  Clin Transl Oncol       Date:  2018-03-13       Impact factor: 3.405

Review 4.  Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer.

Authors:  Megan Morisada; Michael Chamberlin; Clint Allen
Journal:  Head Neck       Date:  2018-02-20       Impact factor: 3.147

Review 5.  Immunomodulatory effects of radiation: what is next for cancer therapy?

Authors:  Anita Kumari; Samantha S Simon; Tomika D Moody; Charlie Garnett-Benson
Journal:  Future Oncol       Date:  2015-12-01       Impact factor: 3.404

6.  Abscopal effect following radiation monotherapy in breast cancer: A case report.

Authors:  Ayaka Azami; Nobuyasu Suzuki; Yusuke Azami; Ichiro Seto; Atai Sato; Yoshinao Takano; Tsuyoshi Abe; Yasushi Teranishi; Kazunoshin Tachibana; Tohru Ohtake
Journal:  Mol Clin Oncol       Date:  2018-07-19

7.  Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.

Authors:  Osama Mohamad; Alberto Diaz de Leon; Samuel Schroeder; Andrew Leiker; Alana Christie; Elizabeth Zhang-Velten; Lakshya Trivedi; Saad Khan; Neil B Desai; Aaron Laine; Kevin Albuquerque; Puneeth Iyengar; Yull Arriaga; Kevin Courtney; David E Gerber; Hans Hammers; Hak Choy; Robert Timmerman; James Brugarolas; Raquibul Hannan
Journal:  Oncoimmunology       Date:  2018-03-15       Impact factor: 8.110

8.  Immunobiology of radiotherapy: new paradigms.

Authors:  Mansoor M Ahmed; Chandan Guha; James W Hodge; Elizabeth Jaffee
Journal:  Radiat Res       Date:  2014-07-18       Impact factor: 2.841

Review 9.  A Current Review of Spatial Fractionation: Back to the Future?

Authors:  Cole Billena; Atif J Khan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-01-23       Impact factor: 7.038

10.  Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma.

Authors:  Lauryn R Werner; Jasdeep S Kler; Monica M Gressett; Maureen Riegert; Lindsey K Werner; Clinton M Heinze; Joseph G Kern; Mahyar Abbariki; Amy K Erbe; Ravi B Patel; Raghava N Sriramaneni; Paul M Harari; Zachary S Morris
Journal:  Radiother Oncol       Date:  2017-09-08       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.